Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Products In Brief

This article was originally published in The Gray Sheet

Executive Summary

The latest product approvals and launches in cardiology, ophthalmology and more.

You may also be interested in...



Merck Partners On Alzheimer’s Diagnostic With GE Healthcare

Merck will use GE Healthcare’s investigational positron emission tomography agent flutemetamol to select patients to enroll in clinical trials for its Alzheimer’s disease drug candidate.

More Patients Should Receive Cardiac Resynchronization Therapy, Heart Groups Say

In revised practice guidelines released Sept. 10, the American Heart Association, the Heart Rhythm Society and the American College of Cardiology Foundation say new evidence shows that many patients with mild heart failure can benefit from cardiac resynchronization devices.

New Products In Brief

Recent launches and approvals include Smith & Nephew’s Legion HK hinge knee implant, Abiomed’s high-flow Impella CP cardiac pump, and Edwards’ ThruPort ProPlege cardioplegia device.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel